Monetta Financial Services Inc. Buys Shares of 20,000 Tempus AI, Inc. $TEM

Monetta Financial Services Inc. acquired a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the second quarter, Holdings Channel.com reports. The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $1,159,000.

Several other hedge funds have also modified their holdings of TEM. Pictet Asset Management Holding SA lifted its stake in Tempus AI by 291.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock worth $2,948,000 after purchasing an additional 36,096 shares during the last quarter. Bogart Wealth LLC raised its stake in shares of Tempus AI by 365,087.5% during the 4th quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock worth $3,450,000 after buying an additional 58,414 shares in the last quarter. Eagle Health Investments LP purchased a new stake in Tempus AI during the first quarter worth about $11,588,000. Alethea Capital Management LLC purchased a new stake in Tempus AI during the fourth quarter worth $1,863,000. Finally, Hussman Strategic Advisors Inc. lifted its holdings in shares of Tempus AI by 100.0% in the fourth quarter. Hussman Strategic Advisors Inc. now owns 42,000 shares of the company’s stock valued at $2,480,000 after purchasing an additional 21,000 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 target price on shares of Tempus AI in a research report on Friday, July 31st. Wolfe Research initiated coverage on Tempus AI in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. BTIG Research decreased their price objective on shares of Tempus AI from $80.00 to $70.00 and set a “buy” rating for the company in a report on Monday, August 3rd. Finally, Guggenheim upped their price target on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Nine analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $64.92.

Tempus AI Price Performance

Tempus AI stock opened at $61.25 on Thursday. The company has a market capitalization of $11.05 billion, a PE ratio of -42.53 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI, Inc. has a one year low of $40.77 and a one year high of $104.32. The business has a 50 day simple moving average of $52.10 and a 200 day simple moving average of $51.16.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter last year, the firm earned ($0.22) EPS. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. On average, sell-side analysts forecast that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Ryan Fukushima sold 33,284 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76. Following the completion of the transaction, the chief executive officer directly owned 167,763 shares in the company, valued at approximately $9,627,918.57. The trade was a 16.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric P. Lefkofsky sold 250,000 shares of Tempus AI stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $42.06, for a total value of $10,515,000.00. Following the completion of the transaction, the chief executive officer owned 200,000 shares in the company, valued at approximately $8,412,000. This represents a 55.56% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 684,424 shares of company stock worth $33,255,565. Company insiders own 24.26% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.